Title:Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing
Camrelizumab and Anlotinib for Prolonged Survival
Volume: 24
Issue: 12
Author(s): ShuangYi Lei*, ShanShan Tian, SongMei Lu, Zhou Qing, JianLin Long, LuChun Li and Dan Yang*
Affiliation:
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical
Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical
Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China
Keywords:
Primary pulmonary lymphoepithelioma-like carcinoma, PD-1, camrelizumab, anlotinib, case report, chemotherapy.
Abstract:
Background: Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of
cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally
have a poor prognosis with overall survival of 22.7 months.
Case Presentation: Here, we report a case of advanced primary pulmonary lymphoepithelioma-like carcinoma.
Initially, the patient underwent a first-line (GP) and a second-line (DP) of chemotherapy, which provided temporary
relief but resulted in varying degrees of myelosuppression. When the disease progressed again, we administered
a third-line treatment consisting of camrelizumab combined with anlotinib.
Result: This resulted in a progression-free survival of over 26 months without significant toxic side effects.
Conclusion: Our findings suggest that combining camrelizumab and anlotinib could lead to a long progressionfree
survival in patients with advanced PPLELC.